Abstract: Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment of cancer, and KRAS G12C-mutant cancer.

Abstract: It relates to a pharmaceutical combination comprising a KRAS G12C inhibitor, in particular 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro [3.3] heptan-2-yl} prop-2-en-1-one (Compound A) and one or more therapeutically active agents selected from a SHP2 inhibitor (e.g. TNO155) and a PD-1 inhibitor, pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutated.

Abstract: An electric beverage preparation machine has an arrangement for processing one or more beverage ingredients to dispense a beverage; a control unit connected to the beverage processing arrangement for controlling the processing of one or more beverage ingredients; a beverage user-selector for requesting a beverage; an operative mode in which such machine is immediately ready to process one or more beverage ingredients; and a start-up mode in which such machine is not ready to process one or more beverage ingredients and is brought into the beverage preparation mode from a low electric consumption standby mode or from an electrically switched off state. The control unit is arranged to store in the start-up mode any beverage request via the beverage user-selector and initiate automatically the processing of one or more beverage ingredients upon entering the operative mode after leaving the start-up mode.

Abstract: A coolant pump includes a pump frame, a driving wheel driven by an engine, a pump wheel driven by the driving wheel, and a clutch which couples the driving wheel with the pump wheel. The clutch comprises a friction surface arranged at the driving wheel, and a clutch disc which corresponds to the friction surface. The clutch disk is connected with and co-rotates with the pump wheel, and is axially shiftable between an engaged and a disengaged position. An axial pretension spring pretensions the clutch disc into the disengaged position. A permanent magnet forces the clutch disc into the engaged position. An electromagnet, when energized, generates a polarization which is opposite to a polarization of the permanent magnet to reduce a total magnetic attraction force of the permanent magnet with respect to the clutch disc and to thereby push the clutch disc into the disengaged position via the pretension spring.

Abstract: A coolant pump includes a rotatable rotor shaft, a pulley wheel which co-rotates with and is supported by the rotor shaft, a pump wheel rotatably supported at the rotor shaft, and an electrically switched wedge-coupled wet friction clutch. The wedge-coupled wet friction clutch comprises a clutch support fixed to the rotor shaft, a clutch ring arranged at a proximal side of the pump wheel, a clutch disk comprising a ferromagnetic element, a static electromagnet which axially pulls the clutch disk to the clutch support into a disengaged position when the static electromagnet is energized, and a wedge coupling mechanism. The wedge coupling mechanism comprises a wedge element and a counter-wedge element which are configured to generate an axial wedge force which axially pushes the clutch disk into an engaged position against the clutch ring when the static electromagnet is not energized and the rotor shaft rotates.

Abstract: Antagonist peptide of the bond between CD47 and a protein belonging to the thrombospondin family has the sequence S1 R1-R2-R3-S-Q-L-L-K-G-R4-R5-R6 and interacts specifically with the C-terminal end of the TSP, at the site of the bond between the TSP and the CD47 receptor. Interaction between the CD47 receptor and the protein is prevented. The peptide can be used in the context of cancer treatments.

Abstract: A coolant pump includes a pump frame, a driving wheel driven by an engine, a pump wheel driven by the driving wheel, and a clutch which couples the driving wheel with the pump wheel. The clutch comprises a friction surface arranged at the driving wheel, and a clutch disc which corresponds to the friction surface. The clutch disk is connected with and co-rotates with the pump wheel, and is axially shiftable between an engaged and a disengaged position. An axial pretension spring pretensions the clutch disc into the disengaged position. A permanent magnet forces the clutch disc into the engaged position. An electromagnet, when energized, generates a polarization which is opposite to a polarization of the permanent magnet to reduce a total magnetic attraction force of the permanent magnet with respect to the clutch disc and to thereby push the clutch disc into the disengaged position via the pretension spring.

Abstract: A coolant pump includes a rotatable rotor shaft, a pulley wheel which co-rotates with and is supported by the rotor shaft, a pump wheel rotatably supported at the rotor shaft, and an electrically switched wedge-coupled wet friction clutch. The wedge-coupled wet friction clutch comprises a clutch support fixed to the rotor shaft, a clutch ring arranged at a proximal side of the pump wheel, a clutch disk comprising a ferromagnetic element, a static electromagnet which axially pulls the clutch disk to the clutch support into a disengaged position when the static electromagnet is energized, and a wedge coupling mechanism. The wedge coupling mechanism comprises a wedge element and a counter-wedge element which are configured to generate an axial wedge force which axially pushes the clutch disk into an engaged position against the clutch ring when the static electromagnet is not energized and the rotor shaft rotates.

Abstract: Antagonist peptide of the bond between CD47 and a protein belonging to the thrombospondin family has the sequence S1 R1-R2-R3-S-Q-L-L-K-G-R4-R5-R6 and interacts specifically with the C-terminal end of the TSP, at the site of the bond between the TSP and the CD47 receptor. Interaction between the CD47 receptor and the protein is prevented. The peptide can be used in the context of cancer treatments.

Abstract: The present invention relates to a composition comprising phenacetin, in particular a Phenacetinum 4CH homeopathic medicament for use in the treatment of cancer.

Abstract: An electric beverage preparation machine has: an arrangement (5?, 5?, 200, 500, 510, 600, 700, 800) for processing one or more beverage ingredients to dispense a beverage; a control unit (2) connected to the beverage processing arrangement for controlling the processing of one or more beverage ingredients; a beverage user-selector (2b, 2b?), such as a push or touch or toggle button or touch screen, for requesting a beverage, the selector being connected to the control unit; an operative mode in which such machine is immediately ready to process one or more beverage ingredients; and a start-up mode in which such machine is not ready to process one or more beverage ingredients and is brought into the beverage preparation mode from a low electric consumption standby mode or from an electrically switched off state.

Abstract: Therapeutic compositions used in the field of angiogenesis include nucleotide sequences of genes, the involvement of the genes in the angiogenesis mechanism having been demonstrated by the Applicant, and including the complementary sequences thereof, the antisense sequences of same, polypeptide sequences coded by the coding parts of the aforementioned genes and antibodies that are directed against the polypeptide sequences and also relate to genetically-modified cells that underexpress or overexpress the above-mentioned genes and to therapeutic compositions containing the cells, which are used to treat angiogenic disorders, and, moreover, relate to methods of diagnosing and/or prognosticating antigenic disorders and to novel methods of screening active compounds in the treatment of the disorders.

Abstract: Nucleotide sequences and the corresponding polypeptide sequences implicated in the regulation of angiogenesis are identified. The nucleotide and polypeptide sequences, or pharmaceutical composition made from such sequences can be used in the clinical study of the angiogenesis process, the prognosis, diagnosis and treatment of pathologies linked to angiogenesis, and in the implementation of pharmaceutical, pharmacogenomic and drug identification trials.

Abstract: Nucleotide sequences and the corresponding polypeptide sequences implicated in the regulation of angiogenesis are identified. The nucleotide and polypeptide sequences, or pharmaceutical compositions made from such sequences, can be used in the clinical study of the angiogenesis process, the prognosis, diagnosis and treatment of pathologies linked to angiogenesis, and in the implementation of pharmacological, pharmacogenomic and drug identification trials.

Abstract: Therapeutic compositions used in the field of angiogenesis include nucleotide sequences of genes, the involvement of the genes in the angiogenesis mechanism having been demonstrated by the Applicant, and including the complementary sequences thereof, the antisense sequences of same, polypeptide sequences coded by the coding parts of the aforementioned genes and antibodies that are directed against the polypeptide sequences and also relate to genetically-modified cells that underexpress or overexpress the above-mentioned genes and to therapeutic compositions containing the cells, which are used to treat angiogenic disorders, and, moreover, relate to methods of diagnosing and/or prognosticating antigenic disorders and to novel methods of screening active compounds in the treatment of the disorders.

Abstract: The invention relates to therapeutic compositions used in the field of angiogenesis, comprising nucleotide sequences of genes, the involvement of said genes in the angiogenesis mechanism having been demonstrated by the Applicant, and including the complementary sequences thereof, the antisense sequences of same, polypeptide sequences coded by the coding parts of the aforementioned genes and antibodies that are directed against said polypeptide sequences. The invention also relates to genetically-modified cells that underexpress or overexpress the above-mentioned genes and to therapeutic compositions containing said cells, which are used to treat angiogenic disorders. Moreover, the invention relates to methods of diagnosing and/or prognosticating antigenic disorders and to novel methods of screening active compounds in the treatment of said disorders.

Abstract: The invention relates to therapeutic compositions used in the field of angiogenesis, comprising nucleotide sequences of genes, the involvement of said genes in the angiogenesis mechanism having been demonstrated by the Applicant, and including the complementary sequences thereof, the antisense sequences of same, polypeptide sequences coded by the coding parts of the aforementioned genes and antibodies that are directed against said polypeptide sequences. The invention also relates to genetically-modified cells that underexpress or overexpress the above-mentioned genes and to therapeutic compositions containing said cells, which are used to treat angiogenic disorders. Moreover, the invention relates to methods of diagnosing and/or prognosticating antigenic disorders and to novel methods of screening active compounds in the treatment of said disorders.

Abstract: Nucleotide sequences and the corresponding polypeptide sequences implicated in the regulation of angiogenesis are identified. The nucleotide and polypeptide sequences, or pharmaceutical compositions made from such sequences, can be used in the clinical study of the angiogenesis process, the prognosis, diagnosis and treatment of pathologies linked to angiogenesis, and in the implementation of pharmacological, pharmacogenomic and drug identification trials.